Charles Schwab Investment Management Inc Immunovant, Inc. Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 661,146 shares of IMVT stock, worth $18.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

661,146

Previous 626,612 5.51%

Holding current value

$18.2 Million

Previous $17.2 Million 5.51%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	N/A	34,534 Added 5.51%	661,146 $18.2 Million
Q1 2025 Sep 15, 2025	SELL	N/A	-34,534 Reduced 5.22%	626,612 $17.2 Million
Q1 2025 May 09, 2025	BUY	N/A	62,170 Added 11.01%	626,612 $17.2 Million
Q4 2024 Feb 06, 2025	BUY	N/A	12,012 Added 2.17%	564,442 $15.5 Million
Q3 2024 Nov 12, 2024	BUY	$27.51 - $27.51 $2.51 Million - $2.51 Million	91,259 Added 19.79%	552,430 $15.2 Million
Q2 2024 Aug 12, 2024	BUY	$25.1 - $31.61 $479,083 - $603,340	19,087 Added 4.32%	461,171 $12.2 Million
Q1 2024 May 08, 2024	BUY	$30.27 - $43.79 $151,471 - $219,125	5,004 Added 1.14%	442,084 $14.3 Million
Q4 2023 Feb 06, 2024	BUY	$31.31 - $44.19 $1.56 Million - $2.2 Million	49,840 Added 12.87%	437,080 $18.4 Million
Q3 2023 Nov 08, 2023	SELL	$18.55 - $39.96 $499,069 - $1.08 Million	-26,904 Reduced 6.5%	387,240 $14.9 Million
Q2 2023 Aug 09, 2023	BUY	$14.2 - $23.75 $364,613 - $609,828	25,677 Added 6.61%	414,144 $7.86 Million
Q1 2023 May 11, 2023	BUY	$15.27 - $19.72 $27,684 - $35,752	1,813 Added 0.47%	388,467 $6.03 Million
Q4 2022 Feb 13, 2023	BUY	$6.59 - $17.75 $538,264 - $1.45 Million	81,679 Added 26.78%	386,654 $6.86 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $617 - $1,000	-157 Reduced 0.05%	304,975 $1.7 Million
Q2 2022 Aug 15, 2022	BUY	$3.38 - $5.65 $23,717 - $39,646	7,017 Added 2.35%	305,132 $1.19 Million
Q1 2022 May 13, 2022	BUY	$5.06 - $8.77 $36,345 - $62,994	7,183 Added 2.47%	298,115 $1.64 Million
Q4 2021 Feb 11, 2022	BUY	$7.33 - $9.32 $157,990 - $200,883	21,554 Added 8.0%	290,932 $2.48 Million
Q3 2021 Nov 16, 2021	SELL	$7.01 - $11.37 $456,056 - $739,709	-65,058 Reduced 19.45%	269,378 $2.34 Million
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $27,720 - $49,690	2,949 Added 0.89%	334,436 $3.54 Million
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $362,486 - $1.37 Million	27,713 Added 9.12%	331,487 $5.32 Million
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $2.01 Million - $2.91 Million	55,181 Added 22.2%	303,774 $14 Million
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $2.1 Million - $3.61 Million	92,890 Added 59.66%	248,593 $8.75 Million
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $2.16 Million - $4.43 Million	155,703 New	155,703 $3.79 Million

Others Institutions Holding IMVT

# of Institutions

195

Shares Held

79M

Call Options Held

401K

Put Options Held

354K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Immunovant, Inc. Transaction History